Sanofi is expanding its insulin portfolio to include the new inhaled insulin, Affreza. While it may not perform in the market at the scale of Lantus, I, for one, am glad that Sanofi is doing this.
Five years ago a small company called VeroScience came out with a new medication called Cycloset, a low-dose immediate-acting formulation of bromocriptine, for improving glucose levels. They had great study results. But because they were a small company with an almost nonexistent marketing budget, the potential of the drug remains to be realized in clinical practice because very few prescribers are aware of its significant benefits. With the marketing power of Sanofi available to spread the information, there is a good chance that Affreza will get the exposure needed to make a difference for the patients who can benefit from it.
Dave Joffe, Editor-in-chief